Compare Cassava Sciences Inc (FLNA) vs Honest Company Inc (HNST) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

HNST trades at $3.93, down 0.76% with a mixed technical picture showing bullish moving averages but overbought RSI signals. The company reported Q1 2026 EPS of $0.01, meeting expectations, but maintains negative profitability with a -5.39% net margin. Revenue declined to $371.32M in 2025 from $378M in 2024, though operating cash flow improved to $15.12M. Analyst sentiment is cautious with 30% buy ratings amid ongoing profitability challenges.

The outlook remains challenging with persistent net losses and revenue volatility creating headwinds for shareholder value. Investment opportunity exists if margin improvements continue, but risks include competitive pressures and failure to achieve sustained profitability. The stock's elevated P/E ratio of 48.83 suggests high expectations that must be met with improved earnings performance.